When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has ...

In its announcement, OpenAI called GPT-Rosalind a "frontier reasoning model built to support research across biology, drug ...

Medicines are uniquely vulnerable to disruptions caused by conflict, as unlike many other goods, they are tightly regulated ...

These documents are written in dense, lawyer-like language that requires individual interpretation from each function; ...

In our final video from the LSX World Congress in Lisbon, Portugal, web editor Nicole Raleigh spoke with Paulo Neves, CMO of ...

The revitalisation of GSK's Blenrep has continued with the news that the NHS in England can use the BCMA-targeting multiple ...

The months-long absence of permanent leadership at the CDC could soon be at an end, after President Trump nominated former ...

In September last year, we reported Servier had advanced its emerging neurology pipeline into the clinical trials stage by ...

The UK has made progress in its efforts to slash set-up times for clinical trials, one of the factors blamed for a decline in ...

The ABPI, in the 3 rd March blog by Pinchas Kahtan, highlighted “early signs of a modest recovery in clinical trial ...

The British Business Bank (BB) has agreed to make a £100 million investment in a new healthcare fund launched by London-based ...

A review of clinical data on amyloid beta-targeting Alzheimer's disease therapies has concluded their efficacy is too modest ...